Skip to main content
Fig. 2 | BMC Nephrology

Fig. 2

From: Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report

Fig. 2

Her clinical course. Day 1 stands for the day when the first dose of gemcitabine-dexamethasone-cisplatin therapy was administered. a LDH levels. The elevation of LDH was observed at the beginning of each chemotherapy. It temporally resolved with chemotherapy initiation, but it worsened after the neutrophil recovery in each course. At the onset of renal-limited TMA, it was observed again probably due to lymphoma itself and inflammation with TMA. It gradually improved with the cessation of GDP therapy and got normalized after the administration of another chemotherapy. b Hemoglobin and platelet levels. The patient already had anemia due to chronic inflammation of refractory lymphoma and myelosuppression due to chemotherapy. However, at the onset of renal-limited TMA, her anemia did not deteriorate; rather, it improved. Also, at the onset of renal-limited TMA, thrombocytosis, not thrombocytopenia, was observed. c Creatinine levels, the amount of urine protein and interventions. The doses of chemotherapy were as follows: 1000 mg/m2 of gemcitabine on days 1 and 8, 33 mg/day of dexamethasone from day 1 to day 4, and 75 mg/m2 of cisplatin on day 1. Abbreviations. GEM: gemcitabine. CDDP: cisplatin. DEX: dexamethasone. RBC: red blood cells

Back to article page